Literature DB >> 18212050

Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.

Yoshitaka Miyagawa1, Hajime Okita, Hideki Nakaijima, Yasuomi Horiuchi, Ban Sato, Tomoko Taguchi, Masashi Toyoda, Yohko U Katagiri, Junichiro Fujimoto, Jun-Ichi Hata, Akihiro Umezawa, Nobutaka Kiyokawa.   

Abstract

Ewing's family tumor (EFT) is a rare pediatric tumor of unclear origin that occurs in bone and soft tissue. Specific chromosomal translocations found in EFT cause EWS to fuse to a subset of ets transcription factor genes (ETS), generating chimeric EWS/ETS proteins. These proteins are believed to play a crucial role in the onset and progression of EFT. However, the mechanisms responsible for the EWS/ETS-mediated onset remain unclear. Here we report the establishment of a tetracycline-controlled EWS/ETS-inducible system in human bone marrow-derived mesenchymal progenitor cells (MPCs). Ectopic expression of both EWS/FLI1 and EWS/ERG proteins resulted in a dramatic change of morphology, i.e., from a mesenchymal spindle shape to a small round-to-polygonal cell, one of the characteristics of EFT. EWS/ETS also induced immunophenotypic changes in MPCs, including the disappearance of the mesenchyme-positive markers CD10 and CD13 and the up-regulation of the EFT-positive markers CD54, CD99, CD117, and CD271. Furthermore, a prominent shift from the gene expression profile of MPCs to that of EFT was observed in the presence of EWS/ETS. Together with the observation that EWS/ETS enhances the ability of cells to invade Matrigel, these results suggest that EWS/ETS proteins contribute to alterations of cellular features and confer an EFT-like phenotype to human MPCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18212050      PMCID: PMC2268432          DOI: 10.1128/MCB.00740-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

1.  Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity.

Authors:  Tatiana Tondreau; Nathalie Meuleman; Alain Delforge; Marielle Dejeneffe; Rita Leroy; Martine Massy; Christine Mortier; Dominique Bron; Laurence Lagneaux
Journal:  Stem Cells       Date:  2005-06-13       Impact factor: 6.277

2.  Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray.

Authors:  Nicoletta Bertani; Paolo Malatesta; Giorgia Volpi; Paolo Sonego; Roberto Perris
Journal:  J Cell Sci       Date:  2005-08-09       Impact factor: 5.285

3.  Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.

Authors:  Richard Smith; Leah A Owen; Deborah J Trem; Jenny S Wong; Jennifer S Whangbo; Todd R Golub; Stephen L Lessnick
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

4.  CD99-positive "Ewing's sarcoma" from mouse-bone marrow-derived mesenchymal progenitor cells?

Authors:  Heinrich Kovar; Alain Bernard
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

5.  Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.

Authors:  Yeny Castillero-Trejo; Susan Eliazer; Lilin Xiang; James A Richardson; Robert L Ilaria
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

6.  EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.

Authors:  Y H Im; H T Kim; C Lee; D Poulin; S Welford; P H Sorensen; C T Denny; S J Kim
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

7.  STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors.

Authors:  R S Hubert; I Vivanco; E Chen; S Rastegar; K Leong; S C Mitchell; R Madraswala; Y Zhou; J Kuo; A B Raitano; A Jakobovits; D C Saffran; D E Afar
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

8.  Ewing's sarcoma: general insights from a rare model.

Authors:  Sean Davis; Paul S Meltzer
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

9.  Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells.

Authors:  Nicolò Riggi; Luisa Cironi; Paolo Provero; Mario-Luca Suvà; Konstantinos Kaloulis; Carlos Garcia-Echeverria; Francesco Hoffmann; Andreas Trumpp; Ivan Stamenkovic
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

10.  Establishment and characterization of a clonal human extraskeletal Ewing's sarcoma cell line, EES1.

Authors:  Masahito Hatori; Hideyuki Doi; Mika Watanabe; Hironobu Sasano; Masami Hosaka; Satoshi Kotajima; Fumihiko Urano; Junichi Hata; Shoichi Kokubun
Journal:  Tohoku J Exp Med       Date:  2006-11       Impact factor: 1.848

View more
  41 in total

Review 1.  The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute.

Authors:  Jilong Yang; Zhiwu Ren; Xiaoling Du; Mengze Hao; Wenya Zhou
Journal:  Stem Cell Investig       Date:  2014-10-27

Review 2.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

Review 3.  Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors.

Authors:  Maria Tsokos; Rita D Alaggio; Louis P Dehner; Paul S Dickman
Journal:  Pediatr Dev Pathol       Date:  2012

4.  High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A.

Authors:  Sapna Vijayakumar; Guizhong Liu; Ioana A Rus; Shen Yao; Yan Chen; Gal Akiri; Luca Grumolato; Stuart A Aaronson
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

Review 5.  Recent advances in the molecular pathogenesis of Ewing's sarcoma.

Authors:  E C Toomey; J D Schiffman; S L Lessnick
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

6.  ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma.

Authors:  Elizabeth T Wiles; Russell Bell; Dafydd Thomas; Mary Beckerle; Stephen L Lessnick
Journal:  Genes Cancer       Date:  2013-11

7.  Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.

Authors:  Bárbara Kunzler Souza; Patrícia Luciana da Costa Lopez; Pâmela Rossi Menegotto; Igor Araujo Vieira; Nathalia Kersting; Ana Lúcia Abujamra; André T Brunetto; Algemir L Brunetto; Lauro Gregianin; Caroline Brunetto de Farias; Carol J Thiele; Rafael Roesler
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

8.  Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma.

Authors:  Patrick P Lin; Yongxing Wang; Guillermina Lozano
Journal:  Sarcoma       Date:  2010-10-05

9.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.

Authors:  Günther H S Richter; Stephanie Plehm; Annette Fasan; Sabine Rössler; Rebekka Unland; Idriss M Bennani-Baiti; Marc Hotfilder; Diana Löwel; Irene von Luettichau; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Heinrich Kovar; Martin S Staege; Carsten Müller-Tidow; Stefan Burdach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

10.  The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma.

Authors:  Ryo Shibuya; Atsuji Matsuyama; Mitsuhiro Nakamoto; Eisuke Shiba; Takahiko Kasai; Masanori Hisaoka
Journal:  Virchows Arch       Date:  2014-07-17       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.